Prestige Consumer Healthcare (NYSE:PBH) Issues Earnings Results

Prestige Consumer Healthcare (NYSE:PBH) issued its quarterly earnings results on Thursday. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Trading Down 0.4 %

Shares of PBH opened at $86.96 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. Prestige Consumer Healthcare has a 1-year low of $60.00 and a 1-year high of $88.36. The company has a market capitalization of $4.30 billion, a P/E ratio of 20.37, a P/E/G ratio of 2.43 and a beta of 0.50. The firm’s 50 day simple moving average is $79.19 and its 200 day simple moving average is $75.34.

Insider Buying and Selling

In other news, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,810 shares of company stock worth $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PBH. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Finally, DA Davidson raised their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.